INVESTIGATION OF IVS14+1G>A POLYMORPHISM OF DPYD GENE IN A GROUP OF BOSNIAN PATIENTS TREATED WITH 5-FLUOROURACIL AND CAPECITABINE

Adverse drug reactions still pose an important clinical problem. Dihydropyrimidine dehydrogenase (DPD) is an enzyme that regulates 5-FU quantities available for anabolic processes and hence affects its pharmacokinetics, toxicity and efficacy. There are several studies describing a hereditary (pharmacogenetic) disorder in which individuals with absent or significantly reduced DPD activity may even develop a life-threatening toxicity following exposure to 5-FU. The most common mutation is known as the DPYD*2A or as the splice-site mutation (IVS14 + 1GA) leading to creation of a dysfunctional protein. An objective behind the study was to ascertain existence of the IVS14 + 1GA mutation among the population of Bosnia and Herzegovina. Our research has undeniably attested to existence of one heterozygote for the DPYD gene mutation, i.e. one heterozygote for IVS14 + 1 G>A, DPYD*2A mutation.